drugset / Trial / NCT01278433

A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China

NCT01278433

Phase 4 Completed 5007 enrolled Sanofi Pasteur, a Sanofi Company
NaSingle-groupOpen-labelPrevention

Summary

The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China. Objective: To describe serious adverse events 30 days after each dose of IMOVAX Polio™ administered at 2, 3, and 4 months of age among infants living in the study cities of China.

Timeline

Start
2010-12
Primary completion
2011-12
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Inactivated Polio Vaccine Vaccine 0.5 ml Intramuscular

Indications